Corona Remedies made a remarkable debut on the stock market, opening with a significant premium. The company’s Rs 655-crore IPO was massively oversubscribed, attracting strong interest from institutional and retail investors alike. This robust demand reflects confidence in Corona Remedies’ solid financial performance, strategic focus on key healthcare areas, and promising earnings potential.
Related Posts
When will Virat Kohli and Rohit Sharma play next for India?
Rohit Sharma and Virat Kohli ended India’s Australia tour with a dominant nine-wicket win, with Rohit scoring an unbeaten 121 and Kohli 74 not out […]
‘Trying to steal Jan Nayak title’: PM slams Rahul; blames RJD for Bihar’s woes
Prime Minister Modi inaugurated significant education and skilling projects in Bihar, including the Jan Nayak Karpoori Thakur Skill University. He subtly criticized Rahul Gandhi over […]
Lamar Jackson injury update: Ravens QB confirms availability vs Steelers
Lamar Jackson’s return injects immense confidence into the Ravens as they face the Steelers in a winner-take-all AFC North showdown. His dual-threat ability, combined with […]